Welcome
The Vaccine and Gene Therapy Institute at Oregon Health & Science University has assembled a multidisciplinary team of scientists to respond to serious viral disease threats, including AIDS, chronic viral infection-associated diseases, newly emerging viral diseases and infectious diseases of the elderly. Our programs are intended to span the continuum between basic and clinical science, in which discoveries are rapidly advanced from the level of molecular and cellular biology through animal models and ultimately into clinical testing. Learn more
VGTI Seminar Series
Recent publications
mBio. September 6, 2024
Bystander monocytic cells drive infection-independent NLRP3 inflammasome response to SARS-CoV-2
Journal of Virology. August 2024
Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins
J Virol. August 29, 2024
A nanobody interaction with SARS-COV-2 Spike allows the versatile targeting of lentivirus vectors
JCI Insight. August 27, 2024
Immune perturbation following SHIV infection is greater in newborn macaques than in infants
PLoS Pathog. August 22, 2024
Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence
Science. August 9, 2024
Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates
JCI Insight. August 8, 2024
Effect of metabolic status on response to SIV infection and antiretroviral therapy in nonhuman primates
PLoS Pathog. August 8, 2024
HIV transcription persists in the brain of virally suppressed people with HIV
Frontiers in Immunology, August 2024
Viral escape mutations do not account for non-protection from SIVmac239 challenge in RhCMV/SIV vaccinated rhesus macaques
Nat Commun. July 19, 2024
Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge
Cell. July 18, 2024
Analysis of the diverse antigenic landscape of the malaria protein RH5identifies a potent vaccine-induced human public antibody clonotype
Cell. July 17, 2024
Natural Malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5
Antiviral Res. June 24, 2024
KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cells
PLoS Pathog. June 17, 2024
MicroRNA-focused CRISPR/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation
ACS Infect Dis. June 11, 2024
3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial Performance
Emerg Infect Dis. June 2024
Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine
Ways to Give
Jay A Nelson Memorial Fund
Your Gift Brings Hope, Please support our mission in memory of Jay Nelson. Your generosity will help contribute to a healthier world, helping OHSU and Doernbecher Children's Hospital make that a world a reality Click to Donate
Donate to VGTI
Your gifts help provide vital resources to conduct innovative research and more.
COVID-19 Efforts - Building a COVID Testing Lab